Strong bones, longer lives: what blood-cancer patients' skeletons are telling doctors

When doctors treat myelodysplastic neoplasms — a group of blood cancers, often shortened to MDS — they watch the blood. The BoHemE study from Dresden University Hospital, published in the journal Leukemia, says they should watch the bones too. Following patients prospectively, the team found bone health is closely tied to survival, mobility and quality of life in MDS — which means osteoporosis care, movement and fracture prevention belong inside cancer care, not beside it. 'If you want to treat MDS comprehensively, you should also keep an eye on bone health,' said Lorenz Hofbauer of the hospital's Osteoporosis Center. The work, funded with €1.8 million (about $2.1 million) over three years by the German Consortium for Translational Cancer Research, turns an overlooked part of the body into practical guidance for clinics today.

SDG 3 · Good health and well-being — Mechanism: tech innovation